Boston Common Asset Management LLC Has $285,000 Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Boston Common Asset Management LLC grew its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 505.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,065 shares of the company’s stock after purchasing an additional 15,080 shares during the period. Boston Common Asset Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $285,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. American Century Companies Inc. raised its holdings in Dr. Reddy’s Laboratories by 8.0% in the 2nd quarter. American Century Companies Inc. now owns 146,823 shares of the company’s stock valued at $11,186,000 after buying an additional 10,855 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Dr. Reddy’s Laboratories by 12.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock valued at $76,455,000 after buying an additional 114,294 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Dr. Reddy’s Laboratories by 6.8% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 4,945 shares of the company’s stock valued at $377,000 after buying an additional 316 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in Dr. Reddy’s Laboratories by 16.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 36,206 shares of the company’s stock valued at $2,759,000 after buying an additional 5,170 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Dr. Reddy’s Laboratories in the 2nd quarter valued at approximately $557,000. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Stock Up 0.5 %

Dr. Reddy’s Laboratories stock opened at $14.91 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92. Dr. Reddy’s Laboratories Limited has a 52-week low of $13.47 and a 52-week high of $16.89. The firm has a 50 day moving average price of $14.86 and a two-hundred day moving average price of $15.55. The firm has a market cap of $12.44 billion, a price-to-earnings ratio of 23.82 and a beta of 0.51.

Analyst Ratings Changes

A number of research analysts recently issued reports on RDY shares. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. Finally, Barclays lowered their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.